Date: Sep 30, 2022
Time: 8:00 am PDT

In September, during prostate cancer awareness month, the Accuray Exchange is hosting a special webinar series to highlight the growing evidence and advances in prostate Stereotactic body radiotherapy (SBRT) and hypofractionated treatments using CyberKnife®️, TomoTherapy®️ and Radixact®️ Systems. 

In this series you will hear from leading experts from the field of prostate radiation oncology, sharing their research and experiences, including mature outcome and treatment-related toxicity data from institutions across the globe. Dr. Vincent Khoo, Consultant Clinical Oncologist, The Royal Marsden NHS Foundation Trust, UK (United Kingdom) will moderate the webinar series. 

Dr Khoo

Moderated by: Vincent Khoo, MB BS, FRACR, FRCR, M.D., Clinical Oncologist, The Royal Marsden, London, UK

Vincent Khoo is a Clinical Oncologist at The Royal Marsden Hospital, Honorary Oncologist at St George’s Hospital, an Honorary Reader at the Institute of Cancer Research, University of London, Adjunct Professor, Department of Medical Imaging and Radiation Sciences, Monash University, and Honorary Associate Professor, Department of Medicine, Melbourne University, and Austin Health, Australia. He specializes in urological cancers, with interests in technical radiotherapy from stereotactic to image-guided intensity-modulated RT; adaptive RT; brachytherapy; multimodality imaging; systemic therapy and clinical trials (phase I – IV studies); as well as evaluation of genetic, and bio-prognostic markers. He is a member of several national and international research study groups, scientific committees, and advisory and editorial boards including the UK NCRI Clinical Study Group, Genetic Prostate Groups, ESTRO, ESMO, and ECCO scientific committees. He has published over 240 papers.

High Dose "HDR-Like" Prostate SBRT - Mature Results from the Original Study and Future Directions
Thursday, September 1st

Dr Fuller

View Recorded Webinar

Read the full paper

Presenter: Donald Fuller, M.D., Radiation Oncologist, Genesis Healthcare Partners, San Diego, CA
Donald B. Fuller, M.D. has been practicing medicine since 1988. He enjoys maximizing the power of technology against cancer by staying at the leading edge of technology innovation and believes in putting new treatments into practice as soon as they become available.

His interests in the specialty include prostate cancer radiotherapy, prostate CyberKnife® Stereotactic Body Radiotherapy (SBRT) and radiation dose escalation for a variety of malignancies through the appropriate application of intensity-modulated radiotherapy (IMRT) and SBRT techniques.

Dr. Fuller is the national principal investigator of a multi-institutional prostate CyberKnife clinical trial. He also has published an original CT-ultrasound fusion prostate brachytherapy technique, as well as original manuscripts in the areas of lung cancer, pediatric cancer, sarcoma, and gynecologic oncology. He is currently a reviewer for several peer-reviewed medical journals, including the International Journal of Radiation Oncology, Biology and Physics, and Brachytherapy. His current areas of active clinical investigation include a new revision to the original CyberKnife SBRT protocol, to examine the use of MRI designed "focal" (less than the whole prostate) SBRT in selected early-stage prostate cancer cases, as well as advancing the use of CyberKnife SBRT for the management for post-radiotherapy locally recurrent and oligometastatic prostate cancer.

When he is not working, Dr. Fuller enjoys a variety of activities, including hiking, physical fitness training, landscaping and nature photography.

If you are unable to access ON24 click here

Extensive Nodal Radiotherapy and Moderately Hypofractionated Simultaneous Integrated Boost in Unfavorable Intermediate-, High-, and Very High-Risk Prostate Cancer: Mature results
Friday, September 9th

Dr. Di Muzio

View Recorded Webinar 

Read the full paper

Presenter: Nadia Di Muzio, M.D., Vita-Salute S. Raffaele University, Director of Radiation Oncology Department, Scientific Institute H San Raffaele, Milan, Italy
Nadia Di Muzio is a Professor at the University of the Studies in Milan, Italy, since 2010, and Professor at San Raffaele University Vita –Salute since 2018. She is the director of the Radiation Oncology Department, Scientific Institute H San Raffaele (HSR) Milano, and authored 200 papers in peer-reviewed scientific journals and several abstracts for international meetings. Her main fields of research include the radiation treatment of prostate cancer with external beam and with brachytherapy. Over 12 years, she developed in-vivo studies in oncology using functional and molecular imaging to define the biological target volume in radiotherapy with a specific interest in PET/Computed Tomography (PET/CT) with 18F-Fluorodeossiglucose (FDG) and 11C-Coline. Based on more than 10 years of experience in hypofractionated IG-IMRT, she also focused on radiobiology to define the biochemical markers correlated with the effectiveness of radiation therapy in moderate hypofractionation and more recently in extreme hypofractionation settings. Since 1999 she has been the Italian Coordinator of the Italian Brachytherapy Group, and since 2005 she has been a member of the European Radiation Oncology Group to promote innovative radiation treatment by using High Technology. She is strongly involved in educational programs and supervises several medical students and Residents in Radiation Oncology. 

Sara Broggi

Presenter: Sara Broggi, Ph.D., Medical Physicist, Scientific Institute H San Raffaele, Milan, Italy
Sara Broggi is a medical physicist at the Radiation Oncology Department, Scientific Institute H San Raffaele (HSR) Milano. She obtained a Ph.D. in 2003 with a thesis titled, ‘clinical application of portal dosimetry’. She is the medical physicist responsible for the TomoTherapy and CyberKnife Systems in the department. Her technical skills and scientific competencies include quality assurance and dosimetry of different radiation machines (Linac, TomoTherapy, CyberKnife); planning optimization for different delivery techniques (2D, 3DCRT, static and rotational IMRT, volumetric arc therapy); planning optimization and dosimetric characterization of TBI techniques; implementation and dosimetric characterization of SBRT; implementation of some planning automatic approaches for volumetric arc techniques. Research activities include planning optimization, outcome/predictive modeling and radiomics.

If you are unable to access ON24 click here

Japanese Experience of CyberKnife® - SBRT for Prostate Cancer
Thursday, September 22nd

Dr. Yasuo Yoshioka

Recorded webinar will be available soon

Read the full paper

Presenter: Yasuo Yoshioka, M.D., Ph.D., Radiation Oncologist, Radiation Oncology Department, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan, Department of Radiation Oncology, Toyota Memorial Hospital, Toyota, Japan
Dr. Yoshioka is a Japanese radiation oncologist and brachytherapist. His main specialty is prostate cancer radiotherapy, including high- and low-dose-rate brachytherapy, intensity-modulated radiation therapy, and stereotactic body radiation therapy (SBRT). He is an expert in high-dose-rate (HDR) brachytherapy and reported the world’s first HDR monotherapy series for prostate cancer. He is now interested in investigating if and how SBRT can mimic or replace HDR brachytherapy. 

Dr. Junji Suzuki
Presenter: Junji Suzuki, Ph.D., Medical Physicist, Department of Radiation Oncology, Toyota Memorial Hospital, Toyota, Japan

Dr. Junji Suzuki is a Medical Physicist at Toyota Motor Corporation, Toyota Memorial Hospital, and Radiotherapy Quality Management Group in Japan since 2015. He obtained his Ph.D. Radiation Oncology and Medical Physics from Sapporo Medical University Graduate School in 2012. His current areas of research are stereotactic radiation therapy and TQM (Total Quality Management) in radiation therapy. He is currently the chair of the QA subcommittee of the CyberKnife committee in Japan.

Single Center Experience of Prostate SBRT in China
Thursday, September 29th, 8pm CST | 9pm JST | 2pm CEST | 8am EDT

Prof Zhang

Presenter: Huo Jun Zhang, M.D., Ph.D., Professor and Chairman of Radiation Oncology Department, Chairman of CyberKnife Center, Changhai Hospital, China
Prof. Zhang specializes in malignant tumor (pancreatic tumor, primary liver cancer, liver metastasis, lung cancer, renal cancer, prostate cancer as well as colon/rectum cancer) treatment with CyberKnife, Stereotactic Body Radiotherapy (SBRT) and interventional radiology.